

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/neoadjuvant-immunotherapy-and-radiation-boosts-response-in-nsclc/29913/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Neoadjuvant Immunotherapy and Radiation Boosts Response in NSCLC

ReachMD Announcer:

Welcome to ReachMD. This medical industry feature is titled “Neoadjuvant Immunotherapy and Radiation Boosts Response in NSCLC,” featuring Chief of Thoracic Surgery at NewYork-Presbyterian and Weill Cornell Medicine, Dr. Nasser Altorki. This video is a production of NewYork-Presbyterian with world-class doctors from Columbia & Weill Cornell Medicine.

Dr. Altorki:

Hello, My name is Nasser Altorki and I'm the Chief of Thoracic Surgery at the New York Presbyterian Hospital Weill Cornell Medicine. I'm also the leader of the experimental Therapeutics program at the Meijer Cancer Center of Weill Cornell Medicine.

The focus of our program is the clinical trials in patients with early stage lung cancer, especially clinical trials that introduce new options for patients with that stage of disease. One of the trials that we conducted recently is a trial looking at the role of low dose radiation, which is delivered over a short period of time, really 3 days combined with immunotherapy. It was, to our knowledge, the 1st in human trial that used low dose radiation combined with immunotherapy.

More patients in the combined modality arm had more than 90% of the cancer cells eliminated and some actually had no cancer cells found in the specimen that we removed at the time of surgery. And this is what it's all about, more options for patients that provide them with excellent outcomes.

ReachMD Announcer:

If you missed any part of this discussion or to find other videos in this series, visit ReachMD.com/industryfeature. This is ReachMD. Be part of the knowledge.